Noortman Wyanne A, Aide Nicolas, Vriens Dennis, Arkes Lisa S, Slump Cornelis H, Boellaard Ronald, Goeman Jelle J, Deroose Christophe M, Machiels Jean-Pascal, Licitra Lisa F, Lhommel Renaud, Alessi Alessandra, Woff Erwin, Goffin Karolien, Le Tourneau Christophe, Gal Jocelyn, Temam Stéphane, Delord Jean-Pierre, van Velden Floris H P, de Geus-Oei Lioe-Fee
Section of Nuclear Medicine, Department of Radiology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.
TechMed Centre, University of Twente, 7522 NB Enschede, The Netherlands.
Cancers (Basel). 2023 May 9;15(10):2681. doi: 10.3390/cancers15102681.
To build and externally validate an [F]FDG PET radiomic model to predict overall survival in patients with head and neck squamous cell carcinoma (HNSCC).
Two multicentre datasets of patients with operable HNSCC treated with preoperative afatinib who underwent a baseline and evaluation [F]FDG PET/CT scan were included (EORTC: n = 20, Unicancer: n = 34). Tumours were delineated, and radiomic features were extracted. Each cohort served once as a training and once as an external validation set for the prediction of overall survival. Supervised feature selection was performed using variable hunting with variable importance, selecting the top two features. A Cox proportional hazards regression model using selected radiomic features and clinical characteristics was fitted on the training dataset and validated in the external validation set. Model performances are expressed by the concordance index (C-index).
In both models, the radiomic model surpassed the clinical model with validation C-indices of 0.69 and 0.79 vs. 0.60 and 0.67, respectively. The model that combined the radiomic features and clinical variables performed best, with validation C-indices of 0.71 and 0.82.
Although assessed in two small but independent cohorts, an [F]FDG-PET radiomic signature based on the evaluation scan seems promising for the prediction of overall survival for HNSSC treated with preoperative afatinib. The robustness and clinical applicability of this radiomic signature should be assessed in a larger cohort.
构建并外部验证一个[F]FDG PET放射组学模型,以预测头颈部鳞状细胞癌(HNSCC)患者的总生存期。
纳入两个多中心数据集,数据集包含接受术前阿法替尼治疗且进行了基线和评估[F]FDG PET/CT扫描的可手术HNSCC患者(欧洲癌症研究与治疗组织:n = 20,Unicancer:n = 34)。勾勒出肿瘤轮廓,并提取放射组学特征。每个队列分别作为训练集和外部验证集用于预测总生存期。使用具有变量重要性的变量搜索进行监督特征选择,选出前两个特征。在训练数据集上拟合使用选定放射组学特征和临床特征的Cox比例风险回归模型,并在外部验证集中进行验证。模型性能用一致性指数(C指数)表示。
在两个模型中,放射组学模型均优于临床模型,验证C指数分别为0.69和0.79,而临床模型的验证C指数分别为0.60和0.67。结合放射组学特征和临床变量的模型表现最佳,验证C指数分别为0.71和0.82。
尽管在两个小的但独立的队列中进行了评估,但基于评估扫描的[F]FDG-PET放射组学特征对于预测接受术前阿法替尼治疗的HNSCC患者的总生存期似乎很有前景。应在更大的队列中评估该放射组学特征的稳健性和临床适用性。